PURPOSE: To assess the safety, efficacy, stability, and predictability after implantation of a toric intraocular copolymer (Collamer) lens (pIOL) to correct high myopic astigmatism. SETTING: Fernández-Vega Ophthalmological Institute, Oviedo, Spain. METHODS: This study evaluated eyes that had implantation of a toric pIOL. Outcome measures were the uncorrected (UDVA) and corrected (CDVA) distance visual acuities (Snellen decimal), refraction, and postoperative complications. RESULTS: The study included 15 eyes of 12 patients (9 women). Preoperatively, the mean manifest spherical refraction was -1.98 diopters (D) +/- 1.32 (SD) (range -0.50 to -5.50 D) and the mean refractive cylinder, -4.85 +/- 0.83 D (range -6.50 to -4.00 D). At 12 months, the mean refractive cylinder was -0.55 +/- 0.52 D (range -1.50 to 0.00 D), with 93.3% of eyes having less than 1.00 D of cylinder. The mean spherical equivalent was -0.31 +/- 0.42 (range -1.00 to 0.75 D), with more than 70% of eyes within +/-0.50 D of the target. For the astigmatic components, 93.3% of eyes were within +/-1.00 D of J0 (r(2) = 0.98) and all eyes were within +/-1.00 D of J45 (r(2) = 0.98). The mean UDVA was 0.70 +/- 0.20 and the mean CDVA, 0.83 +/- 0.12. The overall efficacy index was 0.90. Postoperatively, all eyes had unchanged CDVA or gained 1 or more lines. CONCLUSION: The refractive outcomes and improvement in UDVA and CDVA were rapidly achieved and remained fairly consistent throughout the follow-up period, supporting the use of toric pIOLs in eyes with high astigmatism. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned. Copyright 2010 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
PURPOSE: To assess the safety, efficacy, stability, and predictability after implantation of a toric intraocular copolymer (Collamer) lens (pIOL) to correct high myopic astigmatism. SETTING: Fernández-Vega Ophthalmological Institute, Oviedo, Spain. METHODS: This study evaluated eyes that had implantation of a toric pIOL. Outcome measures were the uncorrected (UDVA) and corrected (CDVA) distance visual acuities (Snellen decimal), refraction, and postoperative complications. RESULTS: The study included 15 eyes of 12 patients (9 women). Preoperatively, the mean manifest spherical refraction was -1.98 diopters (D) +/- 1.32 (SD) (range -0.50 to -5.50 D) and the mean refractive cylinder, -4.85 +/- 0.83 D (range -6.50 to -4.00 D). At 12 months, the mean refractive cylinder was -0.55 +/- 0.52 D (range -1.50 to 0.00 D), with 93.3% of eyes having less than 1.00 D of cylinder. The mean spherical equivalent was -0.31 +/- 0.42 (range -1.00 to 0.75 D), with more than 70% of eyes within +/-0.50 D of the target. For the astigmatic components, 93.3% of eyes were within +/-1.00 D of J0 (r(2) = 0.98) and all eyes were within +/-1.00 D of J45 (r(2) = 0.98). The mean UDVA was 0.70 +/- 0.20 and the mean CDVA, 0.83 +/- 0.12. The overall efficacy index was 0.90. Postoperatively, all eyes had unchanged CDVA or gained 1 or more lines. CONCLUSION: The refractive outcomes and improvement in UDVA and CDVA were rapidly achieved and remained fairly consistent throughout the follow-up period, supporting the use of toric pIOLs in eyes with high astigmatism. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned. Copyright 2010 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Authors: Jose F Alfonso; L Fernández-Vega; C Lisa; P Fernandes; J González-Meijome; R Montés-Micó Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-02-28 Impact factor: 3.117
Authors: J F Alfonso; C Lisa; L Fernández-Vega Cueto; P Fernandes; J M González-Méijome; R Montés Micó Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-09-23 Impact factor: 3.117
Authors: Cari Pérez-Vives; Alberto Domínguez-Vicent; Teresa Ferrer-Blasco; David Madrid-Costa; Robert Montés-Micó Journal: Indian J Ophthalmol Date: 2014-04 Impact factor: 1.848
Authors: Majid Moshirfar; Nour Bundogji; Alyson N Tukan; James H Ellis; Shannon E McCabe; Ayesha Patil; Yasmyne C Ronquillo; Phillip C Hoopes Journal: Clin Ophthalmol Date: 2021-07-06